Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ubavitinib tosylate

The tosylate salt form of NB003, an orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR; CD117), with potential antineoplastic activity. Upon oral administration, ubavitinib specifically targets, binds to and inhibits specific mutant forms of PDGFRa and c-Kit. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases, are upregulated or mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation and resistance to chemotherapy.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AZD 3229 tosylate
AZD-3229 tosylate
AZD3229 tosylate
Code name:NB 003
NB-003
NB003
Chemical structure:N-(4-((5-fluoro-7-(2-methoxyethoxy)quinazolin-4-Yl)amino)phenyl)-2-(4-(propan-2-Yl)-1h-(1,2,3)triazol-1-Yl)acetamide tosylate
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search